Datapoint: Amgen Shores Up Otezla Patent Until 2028

In a victory against Sandoz and Zydus Pharmaceuticals, Amgen last week won a patent case protecting its blockbuster psoriasis drug Otezla from generic competition until 2028. For the treatment of psoriasis, Otezla holds covered or better status for 69% of all insured lives under the pharmacy benefit. It is not covered for 9.5% of lives.

SOURCE: MMIT Analytics, as of 9/22/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 2

Datapoint: Amgen Asks Supreme Court to Hear Repatha Case

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 1

Datapoint: United to Join Massachusetts Duals Demo

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 30

Datapoint: Oscar, Emory to Offer New Health Plan in Georgia

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today